The guideline group was selected to represent those with a special interest in the management of invasive fungal infection (IFI) in patients with haematological malignancy (HM) in the UK and EU. PUBMED, MEDLINE and EMBASE were searched systematically for publications in English from 1981 to 2007 and important abstracts from recent meetings have been included. The writing group produced the draft guideline which was subsequently revised by consensus by members of the Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH). The guideline was then reviewed by a sounding board of approximately 100 UK haematologists, the BCSH and the committee of the British Society for Haematology and amended, again by consensus. Criteria used for levels of evidence and recommendations are as outlined in appendix 3 of the Procedure for Guidelines commissioned by the BCSH (http://www.bcshguidelines.com/process1.asp#App3). The objective of this guideline is to provide healthcare professionals with clear guidance on the management of IFI in patients with HM. The guidance may not be appropriate for patients with other malignancies or AIDS and in all cases individual circumstances may dictate an alternative approach. Studies of patients in all age groups were considered and the guideline makes no distinction between paediatric, adolescent and adult patients in its recommendations. Some of the evidence is unsatisfactory making recommendations difficult.
根据您访问的内容，您可能还对以下内容感兴趣，希望对您有帮助：